Biomerica announces CMS Medicare payment rate of $300 for IBS test

Biomerica (BMRA) announced that the Centers for Medicare & Medicaid Services, CMS, has issued its final pricing determination for the company’s inFoods IBS test, establishing a national Medicare payment rate of $300 under the Clinical Laboratory Fee Schedule, CLFS. The pricing will apply to claims for InFoods IBS tests that Medicare approves and pays with dates of service on or after January 1, 2026. This milestone follows the American Medical Association’s, AMA, approval of a CPT Proprietary Laboratory Analyses, PLA, code for inFoods IBS, which became effective October 1, 2025. The CMS pricing determination establishes a clear national payment rate for the test and this pricing clarity should expand patient access.